{
  "graph_metadata": {
    "query": "How does the tumor hijack the immune system to create an evasion mechanism, and what specific factors does it secrete to inhibit immune response or stimulate its own growth?",
    "generated": "2026-02-07",
    "protocol": "Fuzzy-to-Fact v1.0",
    "confidence": "HIGH"
  },
  "nodes": [
    {
      "id": "HGNC:17635",
      "type": "Gene",
      "label": "CD274",
      "properties": {
        "symbol": "CD274",
        "name": "CD274 molecule",
        "aliases": ["PD-L1", "B7-H1", "PDL1"],
        "ensembl": "ENSG00000120217",
        "uniprot": "Q9NZQ7",
        "entrez": "29126",
        "function": "Plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response."
      }
    },
    {
      "id": "HGNC:11766",
      "type": "Gene",
      "label": "TGFB1",
      "properties": {
        "symbol": "TGFB1",
        "name": "transforming growth factor beta 1",
        "aliases": ["TGFbeta", "CED"],
        "ensembl": "ENSG00000105329",
        "uniprot": "P01137",
        "entrez": "7040",
        "function": "Multifunctional protein that regulates the growth and differentiation of various cell types. Active in immune suppression."
      }
    },
    {
      "id": "HGNC:5962",
      "type": "Gene",
      "label": "IL10",
      "properties": {
        "symbol": "IL10",
        "name": "interleukin 10",
        "aliases": ["CSIF", "TGIF", "IL-10"],
        "ensembl": "ENSG00000136634",
        "uniprot": "P22301",
        "entrez": "3586",
        "function": "Major immune regulatory cytokine with profound anti-inflammatory functions. Inhibits release of pro-inflammatory cytokines from macrophages and monocytes."
      }
    },
    {
      "id": "HGNC:12680",
      "type": "Gene",
      "label": "VEGFA",
      "properties": {
        "symbol": "VEGFA",
        "name": "vascular endothelial growth factor A",
        "aliases": ["VEGF", "VPF"],
        "ensembl": "ENSG00000112715",
        "uniprot": "P15692",
        "entrez": "7422",
        "function": "Induces angiogenesis and protects cells from hypoxia-mediated cell death. Key growth factor for tumor vascularization."
      }
    },
    {
      "id": "HGNC:8760",
      "type": "Gene",
      "label": "PDCD1",
      "properties": {
        "symbol": "PDCD1",
        "name": "programmed cell death 1",
        "aliases": ["PD-1", "PD1", "CD279"],
        "ensembl": "ENSG00000188389",
        "uniprot": "Q15116",
        "entrez": "5133",
        "function": "Inhibitory receptor on T-cells. Delivers inhibitory signals upon binding to CD274/PD-L1, suppressing T-cell activation."
      }
    },
    {
      "id": "HGNC:2505",
      "type": "Gene",
      "label": "CTLA4",
      "properties": {
        "symbol": "CTLA4",
        "name": "cytotoxic T-lymphocyte associated protein 4",
        "aliases": ["CD152", "CTLA-4"],
        "ensembl": "ENSG00000163599",
        "uniprot": "P16410",
        "entrez": "1493",
        "function": "Major negative regulator of T-cell responses. Acts as a decoy receptor with higher affinity for B7 ligands than CD28."
      }
    },
    {
      "id": "HGNC:6059",
      "type": "Gene",
      "label": "IDO1",
      "properties": {
        "symbol": "IDO1",
        "name": "indoleamine 2,3-dioxygenase 1",
        "ensembl": "ENSG00000131203",
        "uniprot": "P14902",
        "entrez": "3620",
        "function": "Catalyzes tryptophan catabolism. Tryptophan shortage inhibits T-cell division and accumulation of catabolites induces T-cell apoptosis. Acts as suppressor of anti-tumor immunity."
      }
    },
    {
      "id": "CHEMBL:3301587",
      "type": "Compound",
      "label": "Durvalumab",
      "properties": {
        "drug_name": "DURVALUMAB",
        "mechanism": "Programmed cell death 1 ligand 1 inhibitor",
        "phase": 4,
        "target": "CD274/PD-L1"
      }
    },
    {
      "id": "CHEMBL:3707227",
      "type": "Compound",
      "label": "Atezolizumab",
      "properties": {
        "drug_name": "ATEZOLIZUMAB",
        "mechanism": "Programmed cell death 1 ligand 1 inhibitor",
        "phase": 4,
        "target": "CD274/PD-L1"
      }
    },
    {
      "id": "CHEMBL:3137343",
      "type": "Compound",
      "label": "Pembrolizumab",
      "properties": {
        "drug_name": "PEMBROLIZUMAB",
        "mechanism": "Programmed cell death protein 1 inhibitor",
        "phase": 4,
        "target": "PDCD1/PD-1"
      }
    },
    {
      "id": "CHEMBL:2108738",
      "type": "Compound",
      "label": "Nivolumab",
      "properties": {
        "drug_name": "NIVOLUMAB",
        "mechanism": "Programmed cell death protein 1 inhibitor",
        "phase": 4,
        "target": "PDCD1/PD-1"
      }
    },
    {
      "id": "CHEMBL:1789844",
      "type": "Compound",
      "label": "Ipilimumab",
      "properties": {
        "drug_name": "IPILIMUMAB",
        "mechanism": "Cytotoxic T-lymphocyte protein 4 inhibitor",
        "phase": 4,
        "target": "CTLA4"
      }
    },
    {
      "id": "CHEMBL:3039545",
      "type": "Compound",
      "label": "Luspatercept",
      "properties": {
        "drug_name": "LUSPATERCEPT",
        "mechanism": "Transforming growth factor beta inhibitor",
        "phase": 4,
        "target": "TGFB1"
      }
    },
    {
      "id": "CHEMBL:3545369",
      "type": "Compound",
      "label": "Epacadostat",
      "properties": {
        "drug_name": "EPACADOSTAT",
        "mechanism": "Indoleamine 2,3-dioxygenase inhibitor",
        "phase": 3,
        "target": "IDO1"
      }
    },
    {
      "id": "NCT:02734160",
      "type": "ClinicalTrial",
      "label": "Galunisertib + Durvalumab in Pancreatic Cancer",
      "properties": {
        "title": "TGF-β Receptor I Kinase Inhibitor (Galunisertib) + Anti-PD-L1 (Durvalumab) in Metastatic Pancreatic Cancer",
        "phase": "1b",
        "status": "COMPLETED",
        "condition": "Metastatic Pancreatic Cancer",
        "interventions": ["Galunisertib", "Durvalumab"],
        "mechanism_tested": "TGF-β pathway blockade + PD-L1 checkpoint inhibition"
      }
    },
    {
      "id": "NCT:03307616",
      "type": "ClinicalTrial",
      "label": "Nivolumab ± Ipilimumab in Sarcoma",
      "properties": {
        "title": "Neoadjuvant Checkpoint Blockade in Undifferentiated Pleomorphic Sarcoma and Dedifferentiated Liposarcoma",
        "phase": "2",
        "status": "ACTIVE_NOT_RECRUITING",
        "condition": "Resectable Sarcoma",
        "interventions": ["Nivolumab", "Ipilimumab", "Radiation Therapy"],
        "mechanism_tested": "PD-1 inhibition ± CTLA-4 inhibition"
      }
    },
    {
      "id": "NCT:04949113",
      "type": "ClinicalTrial",
      "label": "NADINA: Neoadjuvant vs Adjuvant ICI in Melanoma",
      "properties": {
        "title": "Neoadjuvant Ipilimumab + Nivolumab vs Standard Adjuvant Nivolumab in Stage III Melanoma",
        "phase": "3",
        "status": "ACTIVE_NOT_RECRUITING",
        "condition": "Macroscopic Stage III Melanoma",
        "interventions": ["Neoadjuvant ipilimumab + nivolumab", "Adjuvant nivolumab"],
        "mechanism_tested": "Combined CTLA-4 + PD-1 inhibition timing"
      }
    },
    {
      "id": "EFO:0003060",
      "type": "Disease",
      "label": "Non-small cell lung carcinoma",
      "properties": {
        "association_score": 0.67,
        "associated_target": "ENSG00000120217"
      }
    },
    {
      "id": "MONDO:0007254",
      "type": "Disease",
      "label": "Breast cancer",
      "properties": {
        "association_score": 0.55,
        "associated_target": "ENSG00000120217"
      }
    }
  ],
  "edges": [
    {
      "source": "HGNC:17635",
      "target": "HGNC:8760",
      "type": "INHIBITS",
      "properties": {
        "mechanism": "PD-L1 binds to PD-1 receptor on T-cells, delivering inhibitory signals",
        "evidence": "UniProt:Q9NZQ7, UniProt:Q15116",
        "STRING_score": 0.938
      }
    },
    {
      "source": "HGNC:11766",
      "target": "immune_response",
      "type": "SUPPRESSES",
      "properties": {
        "mechanism": "TGF-β inhibits T-cell activation and promotes regulatory T-cell differentiation",
        "evidence": "UniProt:P01137"
      }
    },
    {
      "source": "HGNC:5962",
      "target": "immune_response",
      "type": "SUPPRESSES",
      "properties": {
        "mechanism": "IL-10 inhibits pro-inflammatory cytokine release from macrophages and monocytes, blocks MHC-II expression",
        "evidence": "UniProt:P22301"
      }
    },
    {
      "source": "HGNC:12680",
      "target": "tumor_growth",
      "type": "PROMOTES",
      "properties": {
        "mechanism": "VEGF induces angiogenesis, providing nutrients and oxygen to tumor, enabling growth and metastasis",
        "evidence": "UniProt:P15692"
      }
    },
    {
      "source": "HGNC:6059",
      "target": "T_cell_function",
      "type": "INHIBITS",
      "properties": {
        "mechanism": "IDO1 depletes tryptophan, inhibiting T-cell division and inducing T-cell apoptosis",
        "evidence": "UniProt:P14902"
      }
    },
    {
      "source": "HGNC:2505",
      "target": "T_cell_activation",
      "type": "INHIBITS",
      "properties": {
        "mechanism": "CTLA-4 outcompetes CD28 for B7 ligands (CD80/CD86), blocking co-stimulatory signals",
        "evidence": "UniProt:P16410",
        "STRING_score": 0.955
      }
    },
    {
      "source": "CHEMBL:3301587",
      "target": "HGNC:17635",
      "type": "INHIBITS",
      "properties": {
        "drug_name": "Durvalumab",
        "mechanism": "PD-L1 inhibitor antibody",
        "phase": 4,
        "evidence": "Open Targets GraphQL"
      }
    },
    {
      "source": "CHEMBL:3137343",
      "target": "HGNC:8760",
      "type": "INHIBITS",
      "properties": {
        "drug_name": "Pembrolizumab",
        "mechanism": "PD-1 inhibitor antibody",
        "phase": 4,
        "evidence": "Open Targets GraphQL"
      }
    },
    {
      "source": "CHEMBL:1789844",
      "target": "HGNC:2505",
      "type": "INHIBITS",
      "properties": {
        "drug_name": "Ipilimumab",
        "mechanism": "CTLA-4 inhibitor antibody",
        "phase": 4,
        "evidence": "Open Targets GraphQL"
      }
    },
    {
      "source": "CHEMBL:3039545",
      "target": "HGNC:11766",
      "type": "INHIBITS",
      "properties": {
        "drug_name": "Luspatercept",
        "mechanism": "TGF-β inhibitor",
        "phase": 4,
        "evidence": "Open Targets GraphQL"
      }
    },
    {
      "source": "CHEMBL:3545369",
      "target": "HGNC:6059",
      "type": "INHIBITS",
      "properties": {
        "drug_name": "Epacadostat",
        "mechanism": "IDO1 inhibitor",
        "phase": 3,
        "evidence": "Open Targets GraphQL"
      }
    },
    {
      "source": "HGNC:17635",
      "target": "EFO:0003060",
      "type": "ASSOCIATED_WITH",
      "properties": {
        "disease": "Non-small cell lung carcinoma",
        "score": 0.67,
        "evidence": "Open Targets"
      }
    },
    {
      "source": "HGNC:17635",
      "target": "MONDO:0007254",
      "type": "ASSOCIATED_WITH",
      "properties": {
        "disease": "Breast cancer",
        "score": 0.55,
        "evidence": "Open Targets"
      }
    }
  ]
}
